Clinical trials: Nutrition, Healthy
Healthy, Fatty Liver
Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease
A generic screening study to establish structural and/or functional baselines of specific organs.
- Conditions
- Healthy, Fatty Liver, MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- MASLD (NCT04873258)
- Testing
- Bioimpedence Vector Analysis
- Where
- United Kingdom
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Richmond Research Institute
Healthy, Obese
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants
The main purpose of this study is to evaluate how much LY3502970 gets into the bloodstream and how long it takes the body to eliminate when administered orally as tablet and capsule formulations along with effect of food on…
- Trial name
- NCT05841238
- Testing
- LY3502970
- Where
- 3 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity
Effect of Diltiazem Administration on CP-945,598 Pharmacokinetics
A recently completed clinical drug interaction study of CP-945,598 with ketoconazole, a potent CYP3A inhibitor, showed that coadministration of CP-945,598 with ketoconazole results in an approximately 5-fold increase in…
- Trial name
- NCT00645463
- Testing
- CP-945,598
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
Study Examing The Effect Of Omeprazole On Safety, Tolerability And How The Body Processes An Experimental Drug
Experiment in the test tube indicated that CP-945,598 becomes less soluble with increase of pH (less acidity). Changes in stomach acid levels may affect the solubility of CP-945,598, therefore, alters its availability in the…
- Trial name
- NCT00644839
- Testing
- CP-945,598
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obese, Overweight
A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects
The aim of this 4-weeks randomized double-blind placebo-controlled single and multiple ascending dose study is to assess the Safety and Tolerability of LB54640 in Healthy overweight and obese subjects
- Conditions
- Obese, Overweight, Healthy
- Trial name
- NCT06040372
- Testing
- LB64640
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- LG Chem
Obesity
Safety & Tolerability of a Combination of Antidepressant and Peptic Ulcer Drug in Overweight Healthy Subjects
The hypothesis of this study is that up to 150 mg of sertraline and up to 3 mg of telenzepine will be safe, tolerable, and have the effect of suppressing appetite, when taken in combination daily by mouth by healthy, overweight…
- Trial name
- NCT01155531
- Testing
- Sertraline plus Telenzepine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Theracos
Otherwise Healthy Overweight or Obese
A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese Subjects
This is a Phase 1, randomized, double-blind, placebo-controlled multiple-ascending dose (MAD) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of PHP-303 in otherwise healthy overweight or obese…
- Trial name
- NCT03775278
- Testing
- PHP-303
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- pH Pharma
Overweight or Obesity
A Single Ascending Dose and Multiple Ascending Doses Study of SYH2082 Injection in Healthy Participants
To evaluate the safety and tolerability of single dose and multiple doses of SYH2082 Injection in healthy participants.
- Trial name
- NCT07532655
- Testing
- SYH2082 Injection
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Overweight, Obesity
A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy
The purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight who are otherwise healthy.
- Trial name
- NCT07225556
- Testing
- LY4167586
- Where
- 2 sites in United States, Singapore
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
Dietary Supplements and Personal Energy Tracking Device to Promote and Maintain Healthy Weight
Excessive body weight is becoming a concern around the world, for example over half of the American adult population is overweight or obese.
- Trial name
- NCT00502658
- Testing
- Dietary supplement containing vitamins, minerals, and herbs, Shakes with nutrients and herbs, Control dietary supplement
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Pharmanex
Metabolism and Nutrition Disorder, Obesity
A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects
This trial is conducted in the United States of America. The aim of the trial is to investigate safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) for single doses and multiple doses of…
- Trial name
- NCT02568306
- Testing
- NNC0165-1562
- Where
- United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Overweight and Obesity
The Effect of a High Protein, High Fibre Shake Pre-load on Measures of Satiety and Subsequent Energy Intake
The objective of this study is to determine the effect of a high protein, high fiber supplement pre-load on energy intake at a subsequent meal compared to a low fiber, high carbohydrate Control product in healthy overweight and…
- Trial name
- NCT02979717
- Testing
- High protein, high fiber dietary supplement, Low protein, low fiber comparator
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Beachbody
Healthy Volunteers, Overweight or Obesity
A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight
This is an investigator- and participant-blind, randomized, placebo-controlled, parallel-group, Phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of orally administered…
- Trial name
- NCT07499050
- Testing
- RO7795081
- Where
- 2 sites in China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Overweight , Obesity
Phase 1 Clinical Study of MWN110 Injection in Healthy Participants and Overweight or Obese Participants
This study is a multicenter, randomized, double-blind, placebo-controlled, single and multiple ascending-dose phase 1 clinical trial aimed at evaluating the safety, tolerability, PK, PD, and immunogenicity of MWN110 Injection in…
- Trial name
- NCT07779980
- Testing
- MWN110
- Where
- China
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Healthy Diet, Healthy Nutrition
A Clinical Trial to Evaluate the Efficacy of a Healthy Meal Plan in Improving Health Biomarkers and Promoting Healthy Weight Management.
This is a 16-week, two-arm, hybrid, randomized controlled clinical trial designed to evaluate the effect of the Green Chef Calorie Smart \& Brain Health meal plans on health biomarkers and perceived well-being.
- Trial name
- NCT07140978
- Testing
- Green Chef Meal Delivery Program
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Green Chef Corporation
Obesity
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of NO-13065 in Healthy and Obese Adult Subjects
This clinical trial is the first-in-human study of NO-13065. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses and food effect of NO-13065 in healthy and obese…
- Trial name
- NCT04838639
- Testing
- NO-13065
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Factory, Inc.
Overweight and Obesity, Healthy
the Safety, Tolerability and Pharmacokinetics of Mulberry Twig Alkaloids in Human
This trial is conducted in China. The aim of the trial is to investigate safety, tolerability, and pharmacokinetics of the Mulberry Twig Alkaloids tablets (WH006) in healthy ，overweight and obesity subjects.
- Trial name
- NCT06490263
- Testing
- Experimental: Mulberry Twig Alkaloids Tablets 126 mg single dose in healthy subjects, Mulberry Twig Alkaloids Tablets with single dose in healthy subjects, Mulberry Twig Alkaloids Tablets with multiple dose in healthy subjects
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Beijing Wehand-Bio Pharmaceutical Co., Ltd
Obesity
A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.
The purposes of this study are to: Find out how much of the study drugs are in the blood of healthy subjects after taking multiple doses of VI-0521, metformin and sitagliptan.
- Trial name
- NCT00842400
- Testing
- Metformin, VI-0521, Sitagliptan, Probenecid
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Overweight or Obesity, Healthy
Anti-inflammatory Effect and Associated Mechanisms of Mango Consumption
The primary objective of this project is to provide new knowledge through a comprehensive set of analyses that investigate the complex interplay between regular mango intake, gut microbial structure/ function, mechanisms of…
- Trial name
- MG2 (NCT04726293)
- Testing
- Mango, Control
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Healthy, Obesity, Metabolically
A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624
DR10624 is an Fc fusion protein tri-agonist with balanced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR)/ fibroblast growth factor 21 receptor (FGF21R) agonizing activities.
- Trial name
- NCT05378893
- Testing
- DR10624 for injection
- Where
- New Zealand
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.